S&P 500 Ended Flat at 7,805, but UnitedHealth Beat by 55 Cents and J&J Fell 5%. Why Did Healthcare Split?

Quick take: The S&P 500 closed at 7,805.45, down just 1.79 points, so the index tells you almost nothing. The real action on October 13 was underneath it, and healthcare showed it best: UnitedHealth raised its outlook after a big earnings beat, while Johnson & Johnson fell on a medical-device miss and a talc-litigation charge.

How the indexes finished

According to TheStreet’s closing figures, the Dow slipped 0.35% to 51,670.10, the Nasdaq lost 0.15% to 27,204.38 and the Russell 2000 fell 0.30% to 2,786.13. About 56% of U.S. issues declined. Energy and utilities led the S&P 500’s sectors, while healthcare and technology lagged. Chip names were under pressure after reports of progress on a new Chinese DRAM design, which we covered earlier today.

UnitedHealth: a beat and a higher floor

UnitedHealth reported third-quarter adjusted earnings of $4.69 a share against roughly $4.14 to $4.15 expected, and $2.92 a year earlier. Revenue was $112.69 billion, slightly above estimates but down about 0.4% year over year. The company lifted its 2026 adjusted EPS outlook to at least $20.50, from a prior range of about $19.50 to $20. Its medical care ratio improved to 88.4% from 89.9%, and management credited plan design changes, revised pricing and tighter cost control. The shares were up roughly 4% to 4.5% in early trading, with peers Humana and Elevance Health each up about 2% midday, per 24/7 Wall St.

There are caveats. The medical care ratio included $610 million of favorable prior-period reserve development, which may not repeat. Medicare Advantage enrollment is down 935,000 since the end of 2025, and total medical membership fell to 48.3 million from 50.1 million. Margins are recovering, but the business is shrinking, which is a trade-off worth keeping in view.

Johnson & Johnson: the other side of the sector

TheStreet reported J&J shares down about 5.3% after its MedTech unit missed forecasts and net profit fell 96% on a talc-litigation charge. I could not independently confirm the full earnings detail from a primary filing, so treat the headline numbers as reported rather than final. The point is the contrast: one healthcare giant rewarded for cost discipline, another punished by a legal charge and a weak device segment.

Why it matters

When an index is flat but 56% of stocks fall, dispersion is doing the work. Earnings season is rewarding companies that beat and raise and punishing misses sharply. Meanwhile the backdrop is not easy: Yahoo Finance showed the 10-year Treasury yield near 5.23% intraday, Brent was around $104 early in the session per TheStreet, and the VIX sat near 15.4, a calm reading given those levels.

What to watch next

September U.S. inflation data is due Wednesday and is the main event. A hot print would pressure yields and long-duration stocks; a soft one would test whether bond traders are ready to relax. Also watch the remaining big-bank and health-insurer reports for confirmation of today’s themes, and whether chip weakness spreads beyond memory.

Impact on Indian markets

Indian benchmarks usually take their cue from U.S. yields and the dollar rather than from single-sector earnings. With yields above 5% and foreign investors already net sellers of Indian equities this year, Wednesday’s U.S. inflation reading could set the tone for FPI flows. Indian IT and pharma exporters with large U.S. healthcare exposure may also see sentiment shift on how U.S. insurers and drugmakers guide.

Sources

Disclaimer: This post is for educational and informational purposes only and is not investment advice. Consult a licensed financial advisor before investing.

#TradingTips #TradingSetup #trending #TradingDiscipline #stocktrading #StockInFocus #StockToWatch #US #USMarket #brent #GlobalMarketUpdates #DowJones #Nasdaq #NYSE #UnitedHealth #JohnsonAndJohnson #Humana #ElevanceHealth #EarningsSeason #HealthcareStocks #CPI #SP500 #MedicareAdvantage #ClosingBell

The Conviction And The Caution